Among them, a humanized anti-human interleukin-4 (IL-4)/IL-13 receptor monoclonal antibody, dupilumab; the FDA approved an expanded indication for dupilumab to be used for the treatment of EoE in May 2022. Here, IL4 is linked to eosinophilic esophagitis.